A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Inclusion Criteria:

Patients must have either failed to achieve an American College of Rheumatology 20 %
(ACR20) response at Weeks 12 and 14 in C87050 [NCT00160602], or must have completed the
entire Week 24 assessment of C87050 [NCT00160602] trial.

Exclusion Criteria:

- A diagnosis of any other inflammatory Arthritis (e.g. Psoriatic Arthritis or
Ankylosing Spondylitis)

- A secondary, non-inflammatory type of Arthritis (e.g. Osteoarthritis or Fibromyalgia)
that in the Investigator's opinion is symptomatic enough to interfere with evaluation
of the effect of CDP870 on the patient's primary diagnosis of Rheumatoid Arthritis
(RA)

- Any concomitant biological therapy

- Any experimental therapy, within or outside a clinical